Mineralocorticoid Receptor Antagonist Dosing and Safety Guidelines

Primary Agents

• Spironolactone is a non‑selective mineralocorticoid receptor antagonist that also blocks androgen and progesterone receptors, which contributes to its endocrine side‑effect profile. Endocrine Society recommendation. 1
• Eplerenone is a selective mineralocorticoid receptor antagonist with minimal anti‑androgen activity; it requires 2–3 × higher doses than spironolactone to achieve comparable efficacy. Endocrine Society recommendation. 1

Initiation and Maintenance Dosing

• Spironolactone should be started at 12.5–25 mg once daily and titrated to a maintenance range of 25–100 mg daily; the maximum dose in primary aldosteronism is 400 mg/day. ACC/AHA guideline. 2
• Eplerenone should be started at 25 mg once or twice daily and titrated to a maintenance dose of 50 mg daily; the maximum dose is 200–300 mg/day in divided doses. ACC/AHA guideline. 2

Heart Failure with Reduced Ejection Fraction (HFrEF)

• In patients with eGFR ≥ 50 mL/min/1.73 m², initiate spironolactone 12.5–25 mg daily and, after 4 weeks, increase to 25 mg once or twice daily if serum potassium ≤ 5.0 mmol/L. ACC/AHA guideline. 3
• In the same renal function group, initiate eplerenone 25 mg daily and, after 4 weeks, increase to 50 mg daily if serum potassium ≤ 5.0 mmol/L. ACC/AHA guideline. 4
• For eGFR 30–49 mL/min/1.73 m², start spironolactone 12.5 mg daily (or every other day) and titrate to 12.5–25 mg daily as tolerated. ACC/AHA guideline. 3
• For the same renal range, start eplerenone 25 mg every other day and titrate to 25 mg daily as tolerated. ACC/AHA guideline. 4

Primary Aldosteronism

• Spironolactone: 12.5–25 mg daily for mild disease; 50 mg daily for severe hypokalemia. Titrate every 8–12 weeks in 25–50 mg increments. Target renin de‑suppression is usually achieved with 50–100 mg/day; maximum dose 400 mg/day. Endocrine Society recommendation. 1
• Eplerenone: 25 mg daily (or twice daily) for mild disease; 50 mg twice daily for severe cases. Titrate every 8–12 weeks in 25–100 mg increments. Maximum dose 200–300 mg/day in divided doses. Endocrine Society recommendation. 1

Absolute Contraindications

• Serum creatinine > 2.5 mg/dL in men or > 2.0 mg/dL in women.
• eGFR < 30 mL/min/1.73 m².
• Serum potassium > 5.0 mmol/L.

Monitoring Protocol

• Check serum potassium and creatinine at 2–3 days and again on day 7 after starting therapy. ACC/AHA guideline. 3
• Reduce or discontinue potassium supplements between days 2–4 of initiation. Endocrine Society recommendation. 5
• Perform monthly laboratory monitoring for the first 3 months, then every 3 months thereafter. ACC/AHA guideline. 3
• After any dose adjustment, repeat electrolytes, renal function, and renin 2–3 months later. Endocrine Society recommendation. 5
• If serum potassium rises > 5.5 mmol/L, hold the MRA until potassium falls below 5.0 mmol/L, then restart at a lower dose. ACC/AHA guideline. 2

Risk‑Mitigation Strategies

• Discontinue or reduce potassium supplements at the time of MRA initiation. ACC/AHA guideline. 3
• Counsel patients to avoid high‑potassium foods and non‑steroidal anti‑inflammatory drugs (NSAIDs). ACC/AHA guideline. 3
• Advise temporary cessation of the MRA during episodes of diarrhea, dehydration, or interruption of loop diuretics. ACC/AHA guideline. 4
• Avoid the triple combination of ACE‑inhibitor + ARB + MRA due to excess hyperkalemia risk. ACC/AHA guideline. 4
• Target dietary sodium intake < 85.5 mmol/day (≈ 5 g of salt). Endocrine Society recommendation. 5

Safety and Side‑Effect Profile

• Spironolactone produces greater blood‑pressure reduction than eplerenone at equivalent doses. Endocrine Society evidence. 6
• Gynecomastia occurs in ~ 7 % of patients receiving < 50 mg/day and up to ~ 52 % at > 150 mg/day of spironolactone; dose reduction to ≤ 50 mg/day often resolves the issue. Endocrine Society data. 7
• Eplerenone is better tolerated in men because it does not cause gynecomastia. Endocrine Society observation. 1
• Eplerenone metabolism via CYP3A4 necessitates review of concomitant medications that inhibit or induce this pathway. Endocrine Society guidance. 1

Common Clinical Pitfalls

• Inadequate monitoring leads to hyperkalemia rates of 24–36 % in real‑world practice versus 2–5 % in clinical trials. ACC/AHA analysis. 4
• An early decline in eGFR after MRA initiation often reflects therapeutic effect rather than toxicity; renal function typically stabilizes long‑term. Endocrine Society insight. 5
• Under‑dosing in primary aldosteronism (e.g., using < 50 mg spironolactone) fails to achieve renin de‑suppression, unlike higher doses required for resistant hypertension. Endocrine Society recommendation. 5
• High dietary sodium intake is the most frequent cause of apparent lack of response to MRAs. Endocrine Society recommendation. 5
• Early‑stage gynecomastia can be managed by reducing spironolactone to ≤ 50 mg/day or switching to eplerenone. Endocrine Society guidance. 5

Spironolactone Dosing and Management in Primary Aldosteronism

Maximum Approved Dose

• The recommended upper limit for spironolactone in primary aldosteronism is 400 mg per day when lower doses fail to achieve blood‑pressure or biochemical control. [8][9]

Initiation and Titration Strategy

• Initial dose for the majority of patients is 25–50 mg once daily; this starting range balances efficacy with tolerability. 8
• If target blood‑pressure and renin‑de‑suppression are not reached, the dose may be incrementally increased up to the maximum of 400 mg/day. [8][9]

Blood‑Pressure Efficacy

• Treatment with spironolactone typically lowers systolic blood pressure by 40–60 mm Hg in patients with primary aldosteronism. 8
• As monotherapy, spironolactone achieves blood‑pressure control (<140/90 mm Hg) in approximately 50 % of patients. 8

Safety and Tolerability

Common Adverse Effects

• Gastro‑intestinal discomfort, muscle cramps, and reduced libido are reported side‑effects of spironolactone therapy. 8

Anti‑Androgenic Effects in Men

• When anti‑androgenic symptoms (e.g., gynecomastia) persist despite dose adjustment, switching to eplerenone—which lacks androgen‑receptor antagonism—is advised. The switch typically involves 2–3 × higher daily doses of eplerenone to match spironolactone efficacy. [8][9]

Renal Function Considerations

• In patients with stage 3 chronic kidney disease (eGFR 30–50 mL/min/1.73 m²), a cautious start of 12.5 mg daily (or every other day) is recommended, with careful titration thereafter. 8
• Spironolactone should be avoided when eGFR < 30 mL/min/1.73 m² because of a high risk of prohibitive hyper‑kalaemia. 8

Alternative Mineralocorticoid‑Receptor Antagonists

• Eplerenone requires 2–3 × higher doses (maximum 200–300 mg/day in divided doses) to achieve efficacy comparable to spironolactone. It is the preferred agent for men who develop anti‑androgenic side‑effects on spironolactone. [8][9]
• Amiloride (2.5–10 mg twice daily, up to 10 mg twice daily) can be employed as a second‑line option when mineralocorticoid‑receptor antagonists are not tolerated, acknowledging its lower potency. [8][9]